Bionomics Limited (BNOX)

They are a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Ion channels serve as important mediators of physiological function in the CNS and the modulation of ion channels influences neurotransmission that leads to downstream signaling in the brain. The a7 nicotinic acetylcholine (“ACh”) receptor (“a7 receptor”) is an ion channel that plays an important role in driving emotional responses and cognitive performance. Utilizing their expertise in ion channel biology and translational medicine, they are developing orally active small molecule negative allosteric modulators (“NAMs”) and positive allosteric modulators (“PAMs”) of the a7 receptor to treat anxiety and stressor-related disorders and cognitive dysfunction, respectively. They are advancing their lead product candidate, BNC210, an oral proprietary selective NAM of the a7 receptor, for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”). They expect to initiate their Phase 2 PREVAIL trial for BNC210 for the acute treatment of SAD by the end of 2021 and currently anticipate reporting topline data by the end of 2022.

What do you think will happen with the GLSI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)